RCT | Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer
26 Apr, 2023 | 13:57h | UTCTrastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)